inclisiran

inclisiran. It is a first-in-class, synthetic, small interfering RNA (siRNA) therapeutic agent designed for the long-term management of elevated low-density lipoprotein cholesterol. Developed through a collaboration between Alnylam Pharmaceuticals and The Medicines Company, and now marketed by Novartis, it represents a significant advancement in RNA interference technology for cardiovascular disease. Its approval by the European Medicines Agency and the U.S. Food and Drug Administration offers a novel dosing paradigm for patients with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease.

Mechanism of action

Inclisiran operates by harnessing the natural cellular process of RNA interference to precisely target the synthesis of PCSK9. The drug is a double-stranded siRNA molecule conjugated with triantennary N-acetylgalactosamine, which facilitates highly specific uptake by hepatocytes via the asialoglycoprotein receptor. Once inside the liver cells, the antisense strand of inclisiran integrates into the RNA-induced silencing complex, guiding it to bind and catalyze the degradation of messenger RNA transcripts encoding PCSK9. This inhibition occurs within the cytoplasm, upstream of protein translation, leading to a profound and sustained reduction in circulating PCSK9 levels. Consequently, the increased recycling of LDL receptors on the hepatocyte surface enhances the clearance of low-density lipoprotein cholesterol from the bloodstream.

Clinical trials

The efficacy and safety profile of inclisiran were established in the comprehensive ORION clinical trial program. The pivotal phase III trials, including ORION-9, ORION-10, and ORION-11, were multinational, double-blind, placebo-controlled studies involving thousands of patients. These trials demonstrated that subcutaneous administration of inclisiran, dosed initially and then at three months and every six months thereafter, produced durable reductions of over 50% in LDL cholesterol compared to placebo. The trials met all primary and secondary endpoints, with consistent results across diverse patient populations, including those with heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease. Data from these studies were reviewed by regulatory bodies like the U.S. Food and Drug Administration and formed the basis for its global approvals.

Medical uses

Inclisiran is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL cholesterol. It is administered by a healthcare professional as a subcutaneous injection, with an initial dose, another at three months, and subsequent maintenance doses every six months. This infrequent dosing schedule, a direct result of its long duration of action, aims to improve adherence compared to daily oral therapies or more frequently injected agents like evolocumab or alirocumab. Its use is typically considered for patients who have not achieved their target LDL cholesterol levels with established lipid-lowering regimens.

Adverse effects

Inclisiran is generally well-tolerated, with a safety profile comparable to placebo in the ORION trials. The most commonly reported adverse reactions are mild to moderate injection site reactions, such as erythema, pain, or rash. Other observed effects include arthralgia, bronchitis, and headache, though their incidence was similar in the placebo groups. No significant imbalances were noted in serious adverse events, including incidents related to liver function tests, renal function, or the development of anti-drug antibodies. Ongoing post-marketing surveillance by Novartis and regulators like the European Medicines Agency continues to monitor its long-term safety in broader populations.

Pharmacology

Following subcutaneous administration, inclisiran is rapidly absorbed and distributed primarily to the liver. Its pharmacokinetics are characterized by a quick decline in plasma concentration as the drug is taken up by hepatocytes, with a half-life in the order of hours, which is not directly correlated to its prolonged pharmacodynamic effect. The pharmacodynamics are marked by a slow onset of PCSK9 reduction, reaching maximal suppression approximately 14 days after dosing. The effect on LDL cholesterol follows, with maximal reduction occurring around 30 days post-injection. The silencing effect on PCSK9 mRNA is durable, allowing for the distinctive twice-yearly maintenance dosing regimen after the initial loading doses.

History and development

The journey of inclisiran began with foundational research in RNA interference, a discovery for which Andrew Fire and Craig Mello were awarded the Nobel Prize in Physiology or Medicine. Alnylam Pharmaceuticals, a leader in RNAi therapeutics, pioneered the platform and initiated the discovery program. The development was later advanced through a partnership with The Medicines Company, which conducted the pivotal ORION trials. Following the acquisition of The Medicines Company by Novartis in 2020, the latter assumed global development and commercialization responsibilities. The drug received its first approval from the European Medicines Agency in 2020, followed by endorsement from the U.S. Food and Drug Administration in 2021, marking a new chapter in the management of dyslipidemia.